← Leaderboards
Tito R Mendoza
University Of Tx Md Anderson Can Ctr
$244,000
Attributed
$732,000
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $366K · FY2019–20$500K$375K$250K$125K$0
'19
'20
Funding mix
By agency
NIH$732,000 · 1
By mechanism
R01$732,000 · 1
Top collaborators
- Goldy C George2 shared
- David S. Hong2 shared
Most similar at University Of Tx Md Anderson Can Ctr
Same institution · by research overlap
- Ronald Anthony Depinho$97,148,322
- Peter W Pisters$146,474
- Anil K Sood$29,572,737
- Michael W Andreeff$17,991,896
- Vahid Afshar-Kharghan$3,543,397
Others in their field
Other Emerging Leaders on “Advanced Malignant Neoplasm”
- Leonard Freedman · Leidos Biomedical Research, Inc.$354,493,986
- Leonard Freedmand · Leidos Biomedical Research, Inc.$79,963,641
- Lynn Briscoe · Leidos Biomedical Research, Inc.$47,097,978
- Jennifer Marie Suga · Kaiser Foundation Research Institute$29,218,159
- Stephen F Kry · University Of Tx Md Anderson Can Ctr$28,689,457
- Tareq Al Baghdadi · Saint Joseph Mercy Health System$19,225,531
Research focus
Advanced Malignant NeoplasmAcuteAffectAftercareAdverse EventArthralgiaBackCancer ImmunotherapyCancer TherapyClinical TreatmentAntineoplastic AgentsCohortColitisCombination ImmunotherapyCombined Modality TherapyCommunity Clinical Oncology ProgramCompliance BehaviorCoupledDecision MakingDetectionDeteriorationDiarrheaDisabling SymptomDizziness
Grant awards (2)
Use of Patient-Reported Outcomes in Understanding Symptomatic Adverse Events in Early-Phase Trials of Combination Treatments that Include Immune Checkpoint Inhibitors and Targeted Therapy$366,000
R01 · FY2020 · CA · contact PI
Use of Patient-Reported Outcomes in Understanding Symptomatic Adverse Events in Early-Phase Trials of Combination Treatments that Include Immune Checkpoint Inhibitors and Targeted Therapy$366,000
R01 · FY2019 · CA · contact PI